Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.72 |
| ▸ | IGF1R | P08069 | 6/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | FLT3 | P36888 | 5/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.59 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.59 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.59 |
| ▸ | CDK2 | P24941 | 5/20 | 0.59 |
| ▸ | TTK | P33981 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | CCNH | P51946 | 1/20 | 0.49 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30998031 | 1.00 | EGFR (0.72) | EGFRIGF1RKCNH2FLT3MKNK1 | |
| SCHEMBL14719022 | 0.93 | EGFR (0.74) | EGFRIGF1RKCNH2FLT3MKNK1 | |
| SCHEMBL23294110 | 0.85 | EGFR (0.61) | EGFRIGF1RKCNH2DYRK1BCDK2 | |
| SCHEMBL17831600 | 0.85 | MKNK1 (0.74) | EGFRIGF1RKCNH2FLT3MKNK1 | |
| SCHEMBL14663454 | 0.85 | EGFR (0.72) | EGFRIGF1RKCNH2DYRK1BCDK2 | |
| SCHEMBL30956854 | 0.85 | EGFR (0.62) | EGFRIGF1RKCNH2FLT3MKNK1 | |
| SCHEMBL28463316 | 0.85 | EGFR (0.62) | EGFRIGF1RKCNH2FLT3MKNK1 | |
| SCHEMBL31367926 | 0.84 | EGFR (0.72) | EGFRIGF1RKCNH2FLT3MKNK1 | |
| SCHEMBL14719016 | 0.84 | EGFR (0.72) | EGFRIGF1RKCNH2FLT3MKNK1 | |
| SCHEMBL14717958 | 0.84 | EGFR (1.00) | EGFRIGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTRAZENECA AB (SE) | 2022-12-13 | — | — | US | disclosed |
| US-20210130318-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2021-05-06 | — | — | US | disclosed |
| EP-2736895-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013014448-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130318-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.